Featured Research

from universities, journals, and other organizations

Varying Reductions In Breast Cancer Suggest Hormone Therapy To Blame

Date:
July 6, 2009
Source:
BioMed Central
Summary:
The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers suggest this may be due to varying reductions in the numbers of women taking hormone therapy.

The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers suggest this may be due to varying reductions in the numbers of women taking hormone therapy (HT).

Christina Clarke, Ph.D., led a team of researchers from the Northern California Cancer Center who studied breast cancer incidence data from the largest cancer database available in the US for the years 1997-2004, comparing poor areas against rich and urban areas against rural.

She said, "Between 2001 and 2004, incidence rates of invasive breast cancer declined more than 8% in the United States. "One possible explanation for this is widespread discontinuation of and/or failure to initiate HT. Because this cessation of HT use was more pronounced in rich/urban areas, we wanted to see if there was a corresponding difference in breast cancer incidence between these areas and poor/rural parts of the country".

The researchers found that overall invasive breast cancer incidence fell 13.2%, with greater reductions among women living in urban (-13.8%) versus rural (-7.5%) and low- (-13.0%) or middle- (-13.8%) versus high- (-9.6%) poverty counties. Breast cancer incidence trends for rural counties, which peaked in 1999 and then declined steadily, differed from those observed in urban counties, where rates fell dramatically after 2002. The researchers speculate that this may be due to variations in exposure to the news that HT was associated with breast cancer, they cite a 2007 report that found that the number of newspaper articles about the harmful effects of HT found in the 2002 Women's Health Initiative (WHI) trial correlated with urban residence and likelihood of HT cessation/non-initiation; women in urban areas were potentially exposed to more newspaper articles and had a larger decline in the prevalence of HT use.

Dr. Clarke added that "Understanding what specific populations were involved in the breast cancer declines helps us to better plan prevention efforts for the future, especially with the aging of the baby boomer population into prime breast cancer age."


Story Source:

The above story is based on materials provided by BioMed Central. Note: Materials may be edited for content and length.


Journal Reference:

  1. Amelia K Hausauer, Theresa HM Keegan, Ellen T Chang, Sally L Glaser, Holly Howe and Christina A Clarke. Recent trends in breast cancer incidence in US white women by urban/rural and poverty status. BMC Medicine, (in press) [link]

Cite This Page:

BioMed Central. "Varying Reductions In Breast Cancer Suggest Hormone Therapy To Blame." ScienceDaily. ScienceDaily, 6 July 2009. <www.sciencedaily.com/releases/2009/06/090625201811.htm>.
BioMed Central. (2009, July 6). Varying Reductions In Breast Cancer Suggest Hormone Therapy To Blame. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/06/090625201811.htm
BioMed Central. "Varying Reductions In Breast Cancer Suggest Hormone Therapy To Blame." ScienceDaily. www.sciencedaily.com/releases/2009/06/090625201811.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins